GDTC
Income statement / Annual
Last year (2025), CytoMed Therapeutics Ltd's total revenue was $319.20 K,
an increase of 359.28% from the previous year.
In 2025, CytoMed Therapeutics Ltd's net income was -$3.92 M.
See CytoMed Therapeutics Ltd,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2025
|
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
| Period Ended |
12/31/2025 |
12/31/2024 |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
| Operating Revenue |
$319.20 K |
$69.50 K |
$509.13 K |
$365.60 K |
$0.00 |
$0.00 |
$0.00 |
| Cost of Revenue |
$1.21 M
|
$17.12 K
|
$3.74 K
|
$109.04 K
|
$3.50 K
|
$4.63 K
|
$0.00
|
| Gross Profit |
-$886.56 K
|
$52.38 K
|
$505.39 K
|
-$109.04 K
|
$110.29 K
|
$54.84 K
|
$0.00
|
| Gross Profit Ratio |
-2.78
|
0.75
|
0.99
|
-0.3
|
0
|
0
|
0
|
| Research and Development Expenses |
$2.18 M
|
$1.95 M
|
$1.59 M
|
$1.52 M
|
$1.09 M
|
$1.04 M
|
$439.80 K
|
| General & Administrative Expenses |
$0.00
|
$1.70 M
|
$455.54 K
|
$596.51 K
|
$585.98 K
|
$148.68 K
|
$0.00
|
| Selling & Marketing Expenses |
$0.00
|
$23.78 K
|
$33.40 K
|
$0.00
|
$2.48 K
|
$6.18 K
|
$0.00
|
| Selling, General & Administrative Expenses |
$1.44 M
|
$1.73 M
|
$490.49 K
|
$596.51 K
|
$588.46 K
|
$154.86 K
|
$40.35 K
|
| Other Expenses |
$9.32 K
|
-$496.23 K
|
$0.00
|
$55.52 K
|
-$411.78 K
|
-$12.61 K
|
$171.74 K
|
| Operating Expenses |
$3.63 M
|
$3.18 M
|
$2.08 M
|
$2.17 M
|
$1.27 M
|
$1.18 M
|
$651.88 K
|
| Cost And Expenses |
$4.84 M
|
$3.20 M
|
$2.09 M
|
$2.28 M
|
$1.89 M
|
$1.33 M
|
$651.88 K
|
| Interest Income |
$121.92 K
|
$324.56 K
|
$281.49 K
|
$2.05 K
|
$3.39 K
|
$105.51 K
|
$27.23 K
|
| Interest Expense |
$20.57 K
|
$20.75 K
|
$50.52 K
|
$122.15 K
|
$118.39 K
|
$105.51 K
|
$0.00
|
| Depreciation & Amortization |
$223.17 K
|
$125.05 K
|
$102.51 K
|
$394.70 K
|
$329.74 K
|
$292.52 K
|
$131.98 K
|
| EBITDA |
-$4.30 M |
-$2.44 M |
-$3.89 M |
-$1.47 M |
-$1.42 M |
-$1.03 M |
-$474.60 K |
| EBITDA Ratio |
-13.46
|
-35.18
|
-7.64
|
-4.03
|
0
|
0
|
0
|
| Operating Income Ratio |
-14.16
|
-45.04
|
-3.1
|
-6.25
|
0
|
0
|
0
|
| Total Other Income/Expenses Net |
$587.31 K
|
$608.67 K
|
-$2.56 M
|
-$770.86 K
|
-$900.44 K
|
-$529.63 K
|
-$206.87 K
|
| Income Before Tax |
-$3.93 M
|
-$2.58 M
|
-$4.14 M
|
-$3.05 M
|
-$2.06 M
|
-$1.86 M
|
-$858.75 K
|
| Income Before Tax Ratio |
-12.32
|
-37.07
|
-8.14
|
-8.35
|
0
|
0
|
0
|
| Income Tax Expense |
$0.00
|
$0.00
|
$653.00
|
$1.60 K
|
$0.00
|
$0.00
|
$0.00
|
| Net Income |
-$3.92 M
|
-$2.57 M
|
-$4.14 M
|
-$3.06 M
|
-$2.07 M
|
-$1.94 M
|
-$858.75 K
|
| Net Income Ratio |
-12.27
|
-37
|
-8.14
|
-8.36
|
0
|
0
|
0
|
| EPS |
-0.33 |
-0.22 |
-0.38 |
-0.4 |
-0.3 |
-0.33 |
-0.15 |
| EPS Diluted |
-0.33 |
-0.22 |
-0.38 |
-0.4 |
-0.3 |
-0.33 |
-0.15 |
| Weighted Average Shares Out |
$11.65 M
|
$11.54 M
|
$10.63 M
|
$7.92 M
|
$6.93 M
|
$5.90 M
|
$5.55 M
|
| Weighted Average Shares Out Diluted |
$11.65 M
|
$11.54 M
|
$10.63 M
|
$7.92 M
|
$6.93 M
|
$5.90 M
|
$5.55 M
|
| Link |
|
|
|
|
|
|
|
